Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
The closing price of Regenxbio Inc (NASDAQ: RGNX) was $10.00 for the day, up 2.15% from the previous closing price of $9.79. In other words, the price has increased by $2.15 from its previous closing price. On the day, 1.39 million shares were traded. RGNX stock price reached its highest trading level at $10.12 during the session, while it also had its lowest trading level at $9.4014.
Ratios:
Our analysis of RGNX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 2.93 and its Current Ratio is at 2.93. In the meantime, Its Debt-to-Equity ratio is 0.49 whereas as Long-Term Debt/Eq ratio is at 0.30.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Goldman on February 11, 2025, Downgraded its rating to Neutral and sets its target price to $14 from $38 previously.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on May 12 ’25 when Mills Kenneth T. sold 20,602 shares for $7.91 per share. The transaction valued at 163,046 led to the insider holds 475,103 shares of the business.
KENNETH MILLS bought 20,602 shares of RGNX for $154,927 on May 12 ’25. On Dec 30 ’24, another insider, VITTAL VASISTA, who serves as the Officer of the company, bought 20,041 shares for $7.41 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RGNX now has a Market Capitalization of 501604000 and an Enterprise Value of 367260512. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.20 while its Price-to-Book (P/B) ratio in mrq is 1.83. Its current Enterprise Value per Revenue stands at 2.343 whereas that against EBITDA is -2.598.
Stock Price History:
The Beta on a monthly basis for RGNX is 1.12, which has changed by -0.35358757 over the last 52 weeks, in comparison to a change of 0.11936104 over the same period for the S&P500. Over the past 52 weeks, RGNX has reached a high of $16.25, while it has fallen to a 52-week low of $5.03. The 50-Day Moving Average of the stock is 29.66%, while the 200-Day Moving Average is calculated to be 10.61%.
Shares Statistics:
RGNX traded an average of 1.08M shares per day over the past three months and 1445410 shares per day over the past ten days. A total of 50.12M shares are outstanding, with a floating share count of 45.52M. Insiders hold about 9.25% of the company’s shares, while institutions hold 87.26% stake in the company. Shares short for RGNX as of 1745971200 were 5168219 with a Short Ratio of 4.79, compared to 1743379200 on 5219257. Therefore, it implies a Short% of Shares Outstanding of 5168219 and a Short% of Float of 12.540000000000001.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Its stock is currently analyzed by 6.0 different market analysts. The consensus estimate for the next quarter is $1.08, with high estimates of $2.6 and low estimates of -$1.18.
Analysts are recommending an EPS of between $2.7 and -$3.36 for the fiscal current year, implying an average EPS of $0.23. EPS for the following year is -$1.53, with 7.0 analysts recommending between $0.99 and -$4.4.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 9 analysts. It ranges from a high estimate of $142.89M to a low estimate of $20M. As of the current estimate, Regenxbio Inc’s year-ago sales were $22.3MFor the next quarter, 9 analysts are estimating revenue of $110.02M. There is a high estimate of $222M for the next quarter, whereas the lowest estimate is $21M.
A total of 11 analysts have provided revenue estimates for RGNX’s current fiscal year. The highest revenue estimate was $425.21M, while the lowest revenue estimate was $150M, resulting in an average revenue estimate of $335.87M. In the same quarter a year ago, actual revenue was $83.33MBased on 11 analysts’ estimates, the company’s revenue will be $283.87M in the next fiscal year. The high estimate is $482.9M and the low estimate is $91.84M.
